Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million ...

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...

Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of ...

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) was upgraded by equities researchers at D. Boral Capital from a “hold” ...

Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. Analyst Price Forecast Suggests 121.74% Upside As of ...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a biopharmaceutical company specializing in critical care products, unveiled its financial results for the fiscal full year ending September 30, 2024. The ...

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...